Citi maintains GSK plc at Neutral, PT $17.00
A Citi analyst maintained GSK plc (LON: GSK) at Neutral and a price target of $17.00. Prior to this rating, GSK plc had 9 buy ratings, 10 hold ratings, and 4 sell ratings. For consensus...
Neutral
or
GSK plc News & Analysis
-
-
A Shot of Success: GSK's Arexvy Wins FDA Approval, Pioneering RSV Prevention for Older Adults in Multi-Billion Dollar Market
The FDA has approved GSK Plc's (NYSE: GSK) Arexvy (respiratory syncytial virus vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus...
-
FDA Approves GSK's RSV Vaccine for Older Adults
GSK’s Arexvy respiratory syncytial virus vaccine has been approved by the U.S. Food and Drug Administration for people 60 years old and older.
-
FDA approves GSK's RSV vaccine for older adults, world's first shot against virus
The FDA's approval is a victory for GSK in a race against Pfizer and Moderna to bring a shot that targets respiratory syncytial virus to the market.
-
European stocks lower; banking worries continue to weigh
Investing.com - European stock markets traded lower Wednesday, with worries about the health of the global banking system weighing as the earnings season continues at a pace. At 03:55 ET...
-
GSK rolls out its Shingles vaccine in India
The adult vaccine recommended for people aged 50 years and above, provides protection against shingles - a disease associated with debilitating pain and rashes caused by the reactivation of...
-
GSK to bring Herpes Zoster vaccine Shingrix at one-third of US price: MD
Shingrix is for the prevention of shingles or what is also known as herpes zoster and also post-herpetic neuralgia in people aged 50 and above, says GSK Pharmaceuticals MD Bhushan...
-
Stifel maintains GSK plc at Hold, PT $15.75
A Stifel analyst maintained GSK plc (LON: GSK) at Hold and a price target of $15.75 from a prior price target of %currency%%price%. Prior to this rating, GSK plc had 9 buy ratings, 10 hold...
-
Jefferies maintains GSK plc at Hold, PT $15.75
A Jefferies analyst maintained GSK plc (LON: GSK) at Hold and a price target of $15.75. Prior to this rating, GSK plc had 9 buy ratings, 10 hold ratings, and 4 sell ratings. For consensus...
-
GSK to acquire Canada-based Bellus for $2 billion to gain cough medicine
The takeover will bring GSK a cough medicine that's shown promising results in clinical trials and has advanced through much of the research process
-
GSK To Strengthen Specialty Medicines and Respiratory Pipeline With $2B BELLUS Health Acquisition
GSK Plc (NYSE: GSK) has agreed to acquire the late-stage biopharmaceutical company BELLUS Health Inc (NASDAQ: BLU) for $14.75 a share in cash, representing a total equity value of around...
-
-
Stage Set For Generics As Biden Admin Asks Supreme Court To Hear Skinny Labels Case Between GSK, Teva
The Biden Administration told the U.S. Supreme Court that it should agree to hear a patent appeal over drug labels involving Teva Pharmaceuticals USA Inc (NYSE: TEVA) and GSK Plc (NYSE: GSK)...
-
Biden admin urges Supreme Court to hear ‘skinny labels’ case between Teva, GSK
By Blake Brittain (Reuters) – The Biden Administration told the U.S. Supreme Court on Wednesday that it should agree to hear a patent appeal over drug labels involving Teva...
-
GSK Bets On Scynexis' FDA-Approved Antifungal Drug For Over $500M In Bio Bucks
GSK plc (NYSE: GSK) and Scynexis Inc (NASDAQ: SCYX) have entered into an exclusive license agreement for Brexafemme (ibrexafungerp tablets). The FDA approved the antifungal for vulvovaginal...
-
GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection
Brexafemme complements GSK's industry-leading infectious disease portfolio with an FDA approved treatment for vulvovaginal candidiasis SCYNEXIS will receive an upfront payment of $90 million...
-
Johnson & Johnson Pulls Plug On Large Late-Stage Study Of RSV Vaccine Candidate; GSK, Pfizer Shots Are Under FDA Review
After reviewing its portfolio to prioritize and assessing the respiratory syncytial virus (RSV) vaccine landscape, Janssen, a unit of Johnson & Johnson (NYSE: JNJ), will exit its...
-
GSK Unveils Detailed Phase 3 Data For Jemperli In Frontline Endometrial Cancer Patients
AnaptysBio Inc's (NASDAQ: ANAB) partner GSK Plc (NYSE: GSK) shared interim results from Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial investigating Jemperli (dostarlimab) plus...
-
UBS maintains GSK plc at Sell
An UBS analyst maintained GSK plc (LON: GSK) at Sell and a price target of $13.00. Prior to this rating, GSK plc had 8 buy ratings, 9 hold ratings, and 4 sell ratings. For consensus...
-
Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case'
Executives at GSK Plc (NYSE: GSK), Moderna Inc (NASDAQ: MRNA), and CSL Seqirus, owned by CSL Ltd (OTC: CSLLY), said they are developing or about to test sample human vaccines against bird...
-
Motilal Oswal Financial Services neutral on GlaxoSmithKline Pharmaceuticals; target price: Rs 1300
GlaxoSmithKline Pharmaceuticals, incorporated in the year 1924, is a Large Cap company (having a market cap of Rs 21358.71 Crore) operating in Pharmaceuticals sector.
-
GSK's Chief Scientist Says R&D Focus More On Infectious Disease, HIV Amid Patent Expiration, Dwindling Sales
GSK Plc's (NYSE: GSK) top scientist, Tony Wood, who took the helm of R&D last August, says the R&D department is now delivering results. Wood said he is de-emphasizing R&D in oncology and...
-
How GSK plans to replenish its depleted medicine cabinet
By Maggie Fick STEVENAGE, England (Reuters) – GSK’s chief scientist says an overhaul of the drugmaker’s R&D unit has begun delivering results – citing an RSV vaccine and promising...
-
Influenza and COVID -19 Vaccine Market Report (2022 to 2030) - Pfizer Inc., AstraZeneca plc, Sanofi S.A., GlaxoSmithKline plc and Abbott Laboratories
Newark, New Castle, USA, March 13, 2023 (GLOBE NEWSWIRE) -- The global Influenza and COVID -19 vaccine market will be valued at 278.5 billion in 2030; the spike in cases of COVID pandemic...
-
FDA Fuels Respiratory Syncytial Virus Vaccine Race While Backing GSK's Candidate Soon After Pfizer's
The FDA's Vaccines and Related Biological Products Advisory Committee voted that GSK plc's (NYSE: GSK) available data support the safety and effectiveness of its respiratory syncytial virus...
-
GSK spinoff Haleon forecasts 4-6% revenue growth in 2023
LONDON (Reuters) – Haleon, the world’s biggest standalone consumer health business, on Thursday forecast 4-6% organic revenue growth in 2023.
-
GSK catches up with Pfizer in RSV vaccine race after FDA panel’s backing
(Reuters) – A panel of outside advisers to the U.S. health regulator on Wednesday backed GSK Plc’s respiratory syncytial virus (RSV) vaccine, setting it up for a race with rival Pfizer...
-
Peptide Therapeutics Market Report (2022 to 2030) - Pfizer Inc., Eli Lilly and Company, Sanofi S.A, GlaxoSmithKline plc and Bristol-Myers Squibb Company
Newark, New Castle, USA, March 01, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled, "Global Peptide Therapeutics Market by Application (Metabolic, Cardiovascular...
-
Unilever Q4 sales narrowly miss estimates amid inflation pressures
By Scott Kanowsky Investing.com -- Unilever PLC (LON:ULVR) reported sales growth that was only slightly below analysts' estimates in the fourth quarter, as higher prices helped offset...
-
European shares mixed ahead of key Fed decision
By Scott Kanowsky Investing.com -- European equities were mixed on Wednesday but widely held near the flatline, as investors awaited the highly anticipated release of the Federal Reserve's...
-
Unilever outperforms, edging higher after naming Hein Schumacher as new CEO
By Geoffrey Smith Investing.com -- Shares in Unilever (LON:ULVR) edged higher in London on Monday, outperforming the broader market after the Anglo-Dutch consumer giant named former...
-
European stocks mixed; recession concerns clash with China reopening
By Peter Nurse Investing.com - European stock markets traded mixed Wednesday, as investors digested the further easing of COVID restrictions in China as well as regional recessionary...
-
GSK, Sanofi shares rise after U.S. judge dismisses Zantac cancer link lawsuits
By Scott Kanowsky Investing.com -- Shares in GSK plc (LON:GSK) and Sanofi SA (EPA:SASY) soared on Wednesday after the drugmakers saw tens of thousands of lawsuits involving the heartburn...
-
European stocks edge lower; earnings season in full flow
By Peter Nurse Investing.com - European stock markets traded marginally lower Thursday, with turmoil in the crypto market dampening sentiment while investors continued to digest U.S....
-
GSK Raises Annual Outlook After Shingles Vaccine Helps Boost Q3 Results
By Scott Kanowsky Investing.com -- Shares in GlaxoSmithKline (LON:GSK) moved higher on Wednesday after the drugmaker lifted its full-year earnings and sales outlook following...
-
European Stocks Edge Higher; GSK Shines Ahead of Fed Rate Decision
By Peter Nurse Investing.com - European stock markets edged higher Wednesday, continuing the recent positive trend as investors digest more corporate earnings ahead of the conclusion of the...
-
European Stock Futures Higher; Fed Decision Looms Large
By Peter Nurse Investing.com - European stock markets are expected to open higher Wednesday, continuing the recent positive trend ahead of the conclusion of the crucial Federal Reserve...
-
GSK: Trials for Respiratory Virus Vaccine "Positive"
By Scott Kanowsky Investing.com -- GlaxoSmithKline plc (LON:GSK) has announced that its vaccine for respiratory syncytial virus for adults aged 60 and above showed overall efficacy of...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
